

Estimating virulence costs
from population data
in *Phytophthora infestans*

Josselin Montarry, Roselyne Corbière,
Isabelle Glais & Didier Andrivon

Outline

Introduction

- > some definitions
- > research questions

Methodological approach

Main results

Interpretation and hypotheses

- > costs or no costs?
- > implications for R gene management

Virulence costs

Introduction

Definitions

Virulence cost (fitness cost, fitness penalty)

= disadvantage to individuals bearing the virulence allele
when this allele is useless

Consequences

- > stabilising selection *sensu* Vanderplank
prevents population invasion by virulent isolates
- > basis for gene management strategies
alternance, refuges, etc...

Research questions

- **Do virulence costs exist?**
 - > if they do:
 - Are they quantitatively high?
 - Are they dependent upon resistance genes/ pathogen populations?
- **How to measure them?**
 - > Ideally – pairs of isogenic isolates
 - How to deal with clonal, hard to transform pathogens?
- **What consequences?**
 - > if costs are found:
 - How to explain the persistence of unnecessary virulences?
 - > what gene deployment strategies to use?

Methodological approach

- **Plant material**

- > cultivars with no known R gene(s)
 - 4 cultivars differing in partial resistance levels



Bintje > Ostara >> Kaptah Vandiel > Saturna
—————→
Increasing resistance

- **Isolates**

- > as 'isogenic' as possible
 - 150 isolates with the same SSR profile (10 polymorphic loci)
 - clustering according to presence/absence of virulence to each of the 11 R genes from *S. demissum*

Methodological approach

Methods



Aggressiveness components:

- Latent period
- Lesion size 7 dai
- Spore production 7 dai

Methodological approach

- **Statistical tests**

- > **contrasts between virulent/avirulent bulks**

- Separately for each component & cv
- On a composite aggressiveness index for each cv

$$\gg A_i = \ln [LS*SP/LP]$$

Main results

		Bintje			
		lp	ls	sp	Ai
R1	Av (n=20)	3,38	14,02	352445	14,13
	V (n=112)	3,16	12,68	294259	13,93
	(F _{1,130} ; P)	9.44 / 0.0026**	11 / 0.0012**	6.44 / 0.0123*	4.64 / 0.0331*
R3	Av (n=13)	3,28	13,55	313366	14,01
	V (n=119)	3,18	12,81	301950	13,96
	(F _{1,130} ; P)	1.37 / 0.2438	2.18 / 0.1421	0.16 / 0.6868	0.24 / 0.6274
R4	Av (n=5)	3,37	14,23	349906	14,11
	V (n=127)	3,18	12,83	301231	13,96
	(F _{1,130} ; P)	1.81 / 0.1804	3.25 / 0.0738	1.23 / 0.2697	0.76 / 0.3846
R6	Av (n=128)	3,19	12,92	303997	13,97
	V (n=4)	3,04	11,74	273570	13,76
	(F _{1,130} ; P)	0.94 / 0.3331	1.81 / 0.1803	0.38 / 0.5362	1.15 / 0.2862
R7	Av (n=5)	3,40	13,53	287749	13,90
	V (n=127)	3,18	12,86	303678	13,96
	(F _{1,130} ; P)	2.53 / 0.1141	0.73 / 0.3943	0.13 / 0.7185	0.16 / 0.6941
R8	Av (n=80)	3,27	13,22	309604	13,98
	V (n=52)	3,08	12,36	293030	13,93
	(F _{1,130} ; P)	14.87 / 0.0002***	8.20 / 0.0049**	0.93 / 0.3363	0.51 / 0.4781
R10	Av (n=94)	3,22	12,98	322465	14,03
	V (n=38)	3,11	12,63	255109	13,79
	(F _{1,130} ; P)	4.09 / 0.0453*	1.16 / 0.2828	14.58 / 0.0002***	11.82 / 0.0008***
R11	Av (n=50)	3,25	13,00	323616	14,03
	V (n=82)	3,15	12,81	290550	13,92
	(F _{1,130} ; P)	3.39 / 0.0680	0.38 / 0.5392	3.73 / 0.0556	2.65 / 0.1061

On Bintje:

Two situations:

∅ **Compensation**
(R1, R8, R10)

∅ **No cost**
(R3, R4, R6, R7,
R11)

Main results

Results

	Variété test : Bintje			Kaptah-Vandel			Saturna		
	lp	ls	sp	lp	ls	sp	lp	ls	sp
R1 Av (n=20)	3,38	14,02	352445	4,08	12,71	167365	3,91	10,68	145309
R1 V (n=112)	3,16	12,68	294259	3,77	11,59	189316	3,84	10,57	136709
(F _{1,130} ; P)	9.44 / 0.003	11 / 0.001	6.44 / 0.012	5.26 / 0.023	7.60 / 0.007	1.16 / 0.284	0.28 / 0.595	0.07 / 0.785	0.53 / 0.470
R3 Av (n=13)	3,28	13,55	313366	3,82	13,19	194131	3,97	11,11	145793
R3 V (n=119)	3,18	12,81	301950	3,81	11,61	185325	3,84	10,53	137162
(F _{1,130} ; P)	1.37 / 0.244	2.18 / 0.142	0.16 / 0.687	0.00 / 0.971	10.29 / 0.002	0.12 / 0.725	0.82 / 0.368	1.55 / 0.215	0.36 / 0.547
R4 Av (n=5)	3,37	14,23	349906	3,93	12,23	177089	3,97	10,07	136163
R4 V (n=127)	3,18	12,83	301231	3,81	11,73	186491	3,84	10,61	138085
(F _{1,130} ; P)	1.81 / 0.180	3.25 / 0.074	1.23 / 0.270	0.23 / 0.629	0.42 / 0.520	0.06 / 0.803	0.28 / 0.598	0.56 / 0.456	0.01 / 0.932
R6 Av (n=128)	3,19	12,92	303997	3,82	11,78	185817	3,85	10,59	139384
R6 V (n=4)	3,04	11,74	273570	3,58	10,92	196118	3,96	10,69	94107
(F _{1,130} ; P)	0.94 / 0.333	1.81 / 0.180	0.38 / 0.536	0.70 / 0.405	1.03 / 0.313	0.06 / 0.806	0.19 / 0.661	0.02 / 0.898	3.40 / 0.067
R7 Av (n=5)	3,40	13,53	287749	4,20	12,04	188632	3,97	10,22	134604
R7 V (n=127)	3,18	12,86	303678	3,80	11,74	186033	3,84	10,60	138146
(F _{1,130} ; P)	2.53 / 0.114	0.73 / 0.394	0.13 / 0.718	2.50 / 0.116	0.15 / 0.699	0.00 / 0.945	0.28 / 0.598	0.28 / 0.598	0.03 / 0.874
R8 Av (n=80)	3,27	13,22	309604	3,91	12,21	181049	3,92	10,74	134533
R8 V (n=52)	3,08	12,36	293030	3,67	11,06	193855	3,74	10,35	143364
(F _{1,130} ; P)	14.87 / 0.000	8.20 / 0.005	0.93 / 0.336	5.90 / 0.016	16.25 / 0.000	0.76 / 0.385	3.80 / 0.054	2.02 / 0.158	1.03 / 0.312
R10 Av (n=94)	3,22	12,98	322465	3,87	11,85	189169	3,88	10,52	143729
R10 V (n=38)	3,11	12,63	255109	3,67	11,51	178700	3,78	10,77	123868
(F _{1,130} ; P)	4.09 / 0.045	1.16 / 0.2828	14.58 / 0.000	3.47 / 0.065	1.09 / 0.298	0.44 / 0.510	0.97 / 0.326	0.67 / 0.413	4.61 / 0.034
R11 Av (n=50)	3,25	13,00	323616	3,93	11,99	176696	3,94	10,38	133892
R11 V (n=82)	3,15	12,81	290550	3,75	11,61	191770	3,80	10,72	140524
(F _{1,130} ; P)	3.39 / 0.068	0.38 / 0.539	3.73 / 0.056	3.24 / 0.074	1.54 / 0.217	1.03 / 0.312	2.34 / 0.129	1.38 / 0.242	0.57 / 0.451

On the other cvs :

- Same two situations

∅ Compensation
∅ No cost

- Fewer significant costs than on Bintje

- No effect on Ai

So what?

- **Two ways of having no cost**

☒ Have no cost on any component

- Compensate
 - > trade off LP/ LS*SP

Ü **Different evolutionary consequences (Vanderplank revisited)**

If ☒ :

no (negative) selection

- > stable polymorphism for virulence in mixed cv landscapes (R :r)
- > invasion by virulent races after use of matching R genes
 - ex: R4; R7 = fossil virulences?

If • :

divergent selection

‘super-aggressive’ isolates may emerge if recombination occurs

So what?

Interpretations
& hypotheses

- **Stronger costs on very susceptible cvs**
 - Artifact or reality?
 - see Montarry et al., 2008 JEB > adaptation to prevailing cvs

Ü Consequence for R gene management

simply do not care?

favor cvs with high levels of partial resistance?

diversify cvs?

Special thanks to:

- **INRA blighters**

- Le Rheu

- Roselyne, Isabelle, Bruno, Hervé, Claudine

- **Josselin**

- Ploudaniel

- Daniel, Roland, Jean- Eric

- **Some generous sponsors**

INRA: projets SPE (2004-...)

ACVNPT: CIFRE J. Montarry

MA(A)P(AR): contrats de Branche 'Alimentarité' et 'Résistance'

- **Collaborators**

- SRPV Nord Pas de Calais

- Ludovic, Delphine, Serge

- **Colleagues we talked with:**

- Jérôme Enjalbert,

- Christian Lannou